TY - JOUR
T1 - SWOG 8825
T2 - Melphalan GM-CSF: A phase I study
AU - Poplin, Elizabeth
AU - Smith, Harriet
AU - Behrens, Brent
AU - Redman, Bruce
AU - Flaherty, Lawrence
AU - Neidhart, James
AU - Alberts, David
N1 - Funding Information:
’ Supported by SWOG Grant CA-14028-18. Request for reprints should be addressed to SWOG (SWOG 8825) Operations Office, 5430 Fredericksburg Rd., Suite 618, San Antonio, TX 78229-6197.
PY - 1992/1
Y1 - 1992/1
N2 - The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.
AB - The use of intravenous melphalan at higher doses is limited by severe myelosuppression. It was postulated that GM-CSF would permit the use of higher dose melphalan with only moderate myelosuppression easily manageable in an outpatient setting. Therefore, a phase I study of intravenous melphalan utilizing GM-CSF (recombinant granulocyte-macrophage colony-stimulating factor) support was initiated. Intravenous melphalan at doses of 15-45 mg/m2 was administered every 28 days. GM-CSF was utilized at doses of 10-20 μg/kg/day subcutaneously Days 2-21 on a 28-day cycle. Twenty-five patients received 53 courses of therapy. The dose-limiting toxicities were severe or life-threatening granulocytopenia and thrombocytopenia. Utilizing 20 μg/kg/day GM-CSF, the maximum tolerated dose (MTD) of melphalan is 30 mg/m2 and, with 10 mg/kg/day GM-CSF, the maximum tolerated melphalan dose is only 20 mg/m2. One patient with ovarian cancer achieved a partial response. Because the reported MTD of intravenous melphalan without GM-CSF is 30 mg/m2, GM-CSF has not allowed sufficient escalation of the intravenous melphalan dose for routine outpatient use.
UR - http://www.scopus.com/inward/record.url?scp=0026599287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026599287&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(92)90014-A
DO - 10.1016/0090-8258(92)90014-A
M3 - Article
C2 - 1730428
AN - SCOPUS:0026599287
SN - 0090-8258
VL - 44
SP - 66
EP - 70
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -